Nigeria has secured a major injection of European support for its struggling pharmaceutical sector, with the European Union and France committing €10.2 million to upgrade local drug manufacturing capacity and reduce the country’s dependence on imported medicines.
The agreement, signed during the Nigeria-EU Health Investment Forum in Abuja, establishes a 44-month partnership running through 2028 aimed at transforming how Africa’s most populous nation produces and regulates essential medications. The EU is providing €10 million, with France’s Ministry for Europe and Foreign Affairs adding €200,000 in co-financing.
Branded as the Quality Uplift for Advancing Local Industry in Medicine Standards—QUALIMED—the project targets weaknesses that have left Nigeria importing roughly 70 percent of its pharmaceuticals despite having over 130 registered manufacturing facilities. Those imports drain foreign reserves, create supply vulnerabilities, and deprive Nigerians of employment opportunities in a sector that could anchor industrial growth.
EU Ambassador to Nigeria and ECOWAS Gautier Mignot framed the initiative as leveraging existing partnerships to achieve concrete health outcomes. “Let’s combine the strength of our EU–Nigeria and EU–ECOWAS partnerships with the dynamism of our companies on both sides to achieve a common goal—making healthcare in Nigeria sustainable, diversified, accessible, and affordable for all, while creating jobs and opportunities,” he said, adding that the vision extends beyond Nigeria to West Africa and the broader continent.
France’s Ambassador Marc Fonbaustier tied the commitment to his government’s Global Health Strategy, emphasizing equity and solidarity. “I am very proud that France, through the French Development Agency, is contributing to the implementation of the QUALIMED Nigeria project as part of the Team Europe initiative,” he said. “It reflects our shared values and collective commitment to strengthening health systems, advancing equity, and empowering communities through improved access to essential health products and services.”
Read also: Zuckerberg’s Priscilla Leads $7B Mission To End Human Disease
The centerpiece of QUALIMED is upgrading the National Institute for Pharmaceutical Research and Development into a regional reference center for bioequivalence studies, stability testing, and quality control—functions currently performed abroad at significant cost. Strengthening NIPRD will allow Nigerian pharmaceutical companies to conduct required testing locally, accelerating drug approval timelines and reducing barriers to market entry for locally manufactured products.
Dr. Obi Adigwe, NIPRD’s director-general, welcomed the partnership as essential to building sustainable health infrastructure. “We want to ensure that our people not only get the highest level of healthcare access but that the process also catalyses socioeconomic development, job creation, capacity building, technology transfer, and revenue generation,” he said.
Beyond laboratory modernization, the project will facilitate technology transfers from European manufacturers, train Nigerian scientists and technicians in advanced production techniques, and promote gender equity in biomanufacturing and research—addressing the male-dominated character of Nigeria’s pharmaceutical workforce.
QUALIMED also envisions strengthening clinical research networks, improving Good Manufacturing Practice compliance among local producers, and integrating Nigerian companies into global pharmaceutical supply chains. Those ambitions reflect recognition that Nigeria’s market size—200 million people with growing healthcare needs—could support a robust domestic industry if quality and regulatory standards improve.
The initiative arrives as African governments increasingly recognize pharmaceutical manufacturing as strategic infrastructure, not merely commercial activity. The COVID-19 pandemic exposed the continent’s dangerous reliance on imported vaccines and therapeutics, prompting calls for “health sovereignty” through expanded local production capacity.
Nigeria has particular incentive to succeed. The country faces persistent medicine shortages, widespread circulation of substandard and falsified drugs, and affordability challenges that leave millions without access to essential treatments. A functioning domestic pharmaceutical sector could address all three problems while generating employment and anchoring broader industrial development.
However, past efforts to jumpstart local manufacturing have foundered on obstacles QUALIMED aims to overcome: inadequate testing facilities, weak regulatory enforcement, limited technical expertise, and difficulty accessing international markets due to quality concerns. Whether €10.2 million over 44 months proves sufficient to fundamentally alter those dynamics remains an open question.